Detect drug induced liver injury (DILI) early in the drug discovery process with PerkinElmer's Toxicology Fluorescent Imaging Agent Panel.
Drug-induced liver injury (DILI) is the leading reason for termination of drug discovery research projects and is a significant concern in attrition of new drug molecules reaching phase III clinical trials. DILI can manifest in hepatocellular, cholestatic, and steatotic forms differing in the type and pattern of tissue injury, biomarker expression and inflammation in the liver lobules.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Our fluorescent imaging probes can allow you to image acute drug-induced biological changes in inflammation, tissue destruction, metabolic changes, and vascular leak (edema) in a manner that predicts the potential for drug toxicity, often prior to overt histological signs.
The availability of probes at 680 nm and 750 nm wavelengths further offer the opportunity for multiplex imaging of appropriate probe combinations to maximize information gained from research animals.
The Toxicology In Vivo Fluorescent Agents Panel includes the following five probes:
|Part Number||Fluorescent Probe||Biological Target|
|NEV10054EX||AngioSense 680 EX||Vascular probe:
Leaks into sites of vascular damage or inflammation
|NEV10091||Transferrin-Vivo 750||Transferrin receptor targeted probe:
Iron metabolism marker in liver
|NEV10168||MMPSense 750 FAST||Pan-MMP activatable probe:
Secreted marker of stellate cells, Kupffer cells, macrophages, and neutrophils
|NEV11053||Annexin-Vivo 750||Death/apoptosis probe:
Marker on inflammatory cells; metabolic marker on tumor cells
|NEV11079||RenninSense 680 FAST||Renin activatable probe:
Marker of tissue renin-angiotensin system activity
|Optical Imaging Classification||Fluorescence Imaging|
|Quantity in a Package Amount||6.0 Units|
|Shipping Condition||Blue Ice|
|Unit Size||1 vial|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
User guide for fluorescent imaging probes
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.